Skip to content

Silk'n HST Device Usability and Self Selection Study

Clinical Evaluation of Silk'n HST Self-selection, Labeling Comprehension, and Device Use

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02919007
Enrollment
25
Registered
2016-09-29
Start date
2015-12-31
Completion date
2015-12-31
Last updated
2018-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wrinkles

Brief summary

This is a Usability study, conducted for the purpose of testing Silk'n HST Device usability.

Detailed description

Study objectives: To test the Silk'n HST Device usability, i.e., the self-selection, labeling comprehension, and safe and effective device use by potential end users, under actual use conditions. Additionally, this study was aimed to evaluate if contraindicated subjects self-exclude from use of the device. Investigation Design: The study is a usability study. Twenty five potential participants were enrolled in a single location (shopping mall). Participants received the Silk'n HST device in its original package with the complete user manual and performed a full treatment. Post-treatment questionnaire and labeling comprehension exam were conducted following treatment. Out of the twenty five subjects five participants contraindicated to the study inclusion criteria were self-exclude from use of the device. Success criteria: Using the device, all 20 tested subjects are able to complete device related tasks, including applying and operating the Silk'n device without assistance in a timeframe of up to one hour and with minimal attempts to ask for assistance. Additionally, measurable usability criteria for specific, critical steps, such as time-to-completion, frequency of attempts to ask examiner, numerical ratings, etc., were evaluated using observer evaluation and user post-test questionnaire responses. Sample Size: Twenty five subjects identified as potential end users of the device including five subjects with contraindication to the device were recruited to the study. The number of subjects is appropriate considering the device and user related risks, low probable occurrence and severity of these risks, and the design of the study. Furthermore, usability studies are not seeking statistical significance.

Interventions

DEVICESilk'n HST treatment

Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual

Sponsors

Home Skinovations Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 72 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject is male or female equal to or greater than 18 years of age. * Subject is a potential candidate for purchasing the Silk'n HST device. * Subject has facility with both hands. * Subject is capable of understanding and is willing to sign informed consent.

Exclusion criteria

* Subject with dark brown or black spots, such as large freckles, birth marks, moles or warts on the area to be treated. * Subject with eczema, psoriasis, lesions, open wounds or active infections, such as cold sore in the area to be treated. * Subject with a history of kelodial scar formation, a known sensitivity to light (photosensitivity) or is taking medication that makes the skin more sensitive to light, including non-steroidal anti-inflammatory agents, (e.g., aspirins, ibuprofens, acetaminophen), tetracyclines, phenothiazines, thiazide, diuretics, sulfonyluraes, sulfonamides, DTIC, fluorouracil, vinblastine, griseofulvin, Alpha-Hydroxi Acids (AHAs), Beta-Hydroxi Acids (BHAs), Retin-A®, Accutane® and/or topical retinoids. * Subject with abnormal skin conditions caused by diabetes, for example, or other systemic or metabolic diseases. * Subject currently or has recently been treated with Alpha-Hydroxi Acids (AHAs), Beta-Hydroxi Acids (BHAs), Retin-A®, topical retinoids or azelaic acid. * Subject has been treated with Accutane® (isotretinoin) within the past 6 months. * Subject has been on a steroid regimen within the past 3 months. * Subject has a history of herpes outbreaks in the area of treatment. * Subject suffers from epilepsy. * Subject with an active implant, such as a pacemaker, incontinence device, insulin pump, etc. * Subject with a disease related to photosensitivity, such as porphyria, polymorphic light eruption, solar urticaria, lupus, etc. * Subject with a history of skin cancer or areas of potential skin malignancies. * Subject received radiation therapy or chemotherapy treatments within the past 3 months. * Subject is pregnant or nursing (lactating).

Design outcomes

Primary

MeasureTime frameDescription
Usability Assessment1 hourStudy success is determined according to the ability of all subjects to complete device related tasks, including applying and operating the Device without assistance in a timeframe of up to 1 hour and with minimal attempts to ask for assistance.

Participant flow

Participants by arm

ArmCount
Silk'h HST Treatment
Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual. Measure includes the ability to operate the device correctly according to the user manual. Silk'h HST treatment: Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
25
Total25

Baseline characteristics

CharacteristicSilk'h HST Treatment
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
7 Participants
Age, Categorical
Between 18 and 65 years
18 Participants
Age, Continuous49.2 years
STANDARD_DEVIATION 15.9
Region of Enrollment
United States
25 Participants
Sex: Female, Male
Female
17 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 25
serious
Total, serious adverse events
0 / 25

Outcome results

Primary

Usability Assessment

Study success is determined according to the ability of all subjects to complete device related tasks, including applying and operating the Device without assistance in a timeframe of up to 1 hour and with minimal attempts to ask for assistance.

Time frame: 1 hour

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Silk'n HST TreatmentUsability Assessment25 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026